Telehealth provider Hers launched a longevity vertical called Peptides+ this week, and in an interview with Glossy its chief medical officer, obstetrician and gynecologist Dr. Jessica Shepherd, framed the move as closing a trust gap rather than chasing a trend. The platform opens with five offerings: the peptides sermorelin and glutathione, plus NAD+, L-Carnitine and vitamin B12, the last two of which the company says relate to metabolic health and energy.
Sermorelin is a synthetic fragment that signals the pituitary, and glutathione is an antioxidant compound, both of which have circulated in the injectable wellness market for years with varying levels of oversight. The two names most people actually search for, BPC-157 and TB-500, are not on the launch menu. Hers told Glossy it will add them as soon as regulations allow, which is a quietly significant sentence.
The gray market problem
Shepherd was blunt about where the category currently sits. Sourcing peptides like BPC-157 and sermorelin remains a gray market, and the FDA has only recently announced plans to roll back regulation on certain peptides.
"There is a very big trust gap, [while] people's appetite for, and curiosity about, it is very big," Shepherd told Glossy. Her pitch is reputability and supply chain control, which is a reasonable thing to sell into a market where the alternative is a website with no name on it.
The 55 percent nobody has reached
The one hard figure here comes from the company's own research. A survey commissioned by Hims and Hers from Culture Co-op in October 2026 found 55% of surveyed U.S. adults are interested in or curious about peptide therapies, while 9% say they currently use them.
That is a brand-commissioned number, not independent research, and it should be read as such. It is also the entire business case: a six-to-one gap between curiosity and use.
Peptides beyond the bro market
"Peptides, if you think of it, typically have been in the bro world, right?" Shepherd said, arguing that female consumers want somewhere they can get questions answered. That is a real and underserved positioning, and it is more honest than most category entries.
What the interview does not include is a single clinical trial, outcome figure or published study behind any of the five launch compounds. For a platform built on clinical-led guidance, that is a lot of infrastructure described and no data cited.
The regulatory wait
Hers is betting that trust, not efficacy evidence, is the scarce resource in this category. Whether BPC-157 and TB-500 ever join the menu depends on an FDA decision that has not happened yet.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.